Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Interest Income

Income earned on cash, deposits, and investments held by the company.

Prime Medicine, Inc.NASDAQ: PRME

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income grows in line with its trailing trend

Q1 FY2026 interest income of $1.48M rose 25.3% year over year, ahead of the +23.6% change in trailing-twelve-month interest income. Sequentially, it rose 36.7% from the prior quarter.

Context

  • Interest income amounted to 89.6% of revenue in FY2025, down 28.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.3% holds above the trailing-twelve-month pace of +23.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.48M+36.7% QoQ
Last fiscal yearDec 2025
$4.15M+17.8% YoY
LTMMar 2026
$4.98M+23.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.3%——
1 year+17.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
4.15M USD
Year-over-year change
+17.8%

Interest Income vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 interest income of $4.98M is the 4th highest of the 7 companies compared; the peer median is $4.52M.
  • Its year-over-year change of +23.6% is the 2nd highest of 5, against a peer median of -35.8%.
  • Interest income amounts to 123.4% of revenue for PRME, versus a peer median of 3.9%.
PRME Competitors Peer median
Interest Income for PRME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$31.41M -30.6%—20.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$25.8M -41.1%+50.6%39.0%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$9.04M +57.4%——
PRMEPrime Medicine, Inc.LTM Mar 2026$4.98M +23.6%—123.4%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 ——0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 —+20.3%0.0%
EDITEditas Medicine, Inc.LTM Mar 2026-$1.51M -112.9%+14.6%3.9%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding PRME) $4.52M-35.8%+20.3%3.9%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.98M4.63M
Cost of Revenue00007.32M
Gross Profit0002.98M(2.69M)
Gross Margin———100.0%-58.1%
Research & Development70.55M86.73M147.91M155.29M160.64M
Selling, General & Admin13.92M29.82M43.39M50.16M52.35M
Operating Expenses84.47M116.54M204.79M205.45M205.66M
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
EBITDA(165.29M)(120.55M)(186.64M)(189.75M)(195.76M)
EBITDA Margin———-6361.2%-4226.2%
Operating Income(84.47M)(116.54M)(204.79M)(202.47M)(208.35M)
Operating Margin———-6787.4%-4498.1%
Interest Income0003.52M4.15M
Interest Expense00000
Other Income / Expenses(81.38M)(6.23M)6.38M6.59M7.21M
Income Before Tax(165.85M)(122.77M)(198.41M)(195.88M)(201.14M)
Pre-Tax Margin———-6566.6%-4342.4%
Income Tax Expense(486K)(948K)(279K)00
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Net Margin———-6566.6%-4342.4%
EPS (Basic)(1.92)(1.46)(2.18)(1.65)(1.35)
EPS (Diluted)(1.92)(1.46)(2.18)(1.65)(1.35)
Weighted Avg Shares95.73M97.21M90.97M118.6M148.76M
Weighted Avg Shares (Diluted)95.73M97.21M90.97M118.6M148.76M

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.